AvenCell to Present New Data from Universal Switchable CAR T Cell Therapy Programs at 65th American Society of Hematology Annual Meeting and Exposition

Busy business people walking

Poster presentation of updated safety and efficacy data for AVC-101 in relapsed/refractory acute myeloid leukemia, providing clinical proof of concept with best-in-class efficacy signal in late-line AML patients, demonstrating rapid CAR T cell on-off control mechanism of Universal Switchable CAR platform, and impressive durability of responses

Poster presentation of preclinical functional characterization and optimization of Switchable Allogeneic CAR T Cells for Targeting CD19 and CD20 in B Cell Malignancies

WATERTOWN, MA.– Dec. 8, 2023 — AvenCell Therapeutics, Inc., a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies, today announced that expanded clinical safety and efficacy data from its leading Universal Switchable CAR T Cell (“UniCAR”) Therapy program and preclinical data from its Switchable Allogeneic CAR platform will be revealed in poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition on December 09-12, 2023, in San Diego, California.

“We are excited to showcase the power of our Universal Switchable CAR platform at ASH, which has the potential to address the longstanding efficacy and safety challenges that have limited a wider application of cellular immunotherapies to date,” said Andrew Schiermeier, Ph.D., Chief Executive Officer, AvenCell Therapeutics. “The clinical data presented by Dr. Elisa Sala demonstrates the promise of the platform to successfully provide a clear therapeutic window for CD123 in R/R AML – a challenge that has notoriously been elusive in many past attempts. The preclinical data presented by Dr. Johannes Spehr additionally shows the promise of our Switchable Allogeneic CAR platform in other indications, including B cell lymphomas, where relapse and access to existing CAR-T products are still problematic.”

Poster Presentation [#3465]: Updated Results from a Phase I Dose Escalation Study of the Rapidly-Switchable Universal CAR-T Therapy UniCAR-T-CD123 in Relapsed/Refractory AML
Presenting Author:
 Dr. Elisa Sala
Date/Time: Sunday, December 10, 2023, 06:00 PM – 8:00 PM PST

Location: Halls G-H (San Diego Convention Center)

This presentation will include updated safety and efficacy data from the first-in-human phase 1 dose escalation study of AVC-101 in patients with R/R AML, designed to assess safety and tolerability and identify an MTD.  Secondary and exploratory objectives include efficacy, biological activity and PK.

The abstract reports results as of July 7, 2023 for 15 heavily pre-treated R/R AML patients with a median of three prior lines of therapies (min-max: 1-7 lines), and four patients in CR that were MRD positive for whom change in MRD disease load was measured. Updated data includes durable responses in patients lasting more than six months and will be included in the Poster during the ASH Conference.

Poster Presentation [#2059]: Functional Characterization and Optimization of Switchable Allogeneic Chimeric Antigen Receptor T Cells for Targeting CD19 and CD20 in B Cell Malignancies
Presenting Author: 
Dr. Johannes Spehr
Date/Time: Saturday, December 09, 2023, 05:30 PM – 7:30 PM PST

Location: Halls G-H (San Diego Convention Center)
This presentation will include data from preclinical optimization and characterization of Switchable Allogeneic CAR T cells for the treatment of B cell malignancies by simultaneous targeting CD19 and CD20 to prevent antigen escape. The program presents an advancement of AvenCell’s proprietary CAR platform in combination with the use of its allogeneic T cells, which are gene-engineered in three loci to provide a safe and persistent cell product.

The abstract reports key results of in vitro and in vivo studies revealing the profound efficacy of Switchable Allogeneic CAR T cells against advanced tumors and tumors expressing either both or only one of the target antigens.

Abstracts outlining AvenCell’s accepted data at ASH are available on the ASH conference website.

Please find here the Press release in pdf.

Share This Post

Susan Buttler

VP, Clinical Operations

Susan is the Vice President, Clinical Operations for Avencell; she brings over 30 years of experience in Global Clinical Operations to AvenCell’s Clinical Operations team.  Prior to joining Avencell, Susan had multiple senior level roles within the Biotech, Pharmaceutical and CRO organizations.  Susan has experience in leading clinical operations teams to successful study execution and multiple global regulatory submissions. Susan is a graduate of the University of Wisconsin-Milwaukee with a Bachelor of Science in Medical Technology.

Andrew Schiermeier, Ph.D.

Chief Executive Officer

Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you.

Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you. Want to discuss my work or a challenge you’re facing?  Leave your details and I’ll get back to you.